Φορτώνει......
Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD
BACKGROUND: Formoterol fumarate inhalation solution (FFIS; Perforomist(®)) is a long-acting β(2)-agonist (LABA) marketed in the US as a nebulized COPD maintenance treatment. Because long-term LABA use was associated with a potential increased risk of exacerbation or death in asthma patients, the US...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Int J Chron Obstruct Pulmon Dis |
|---|---|
| Κύριοι συγγραφείς: | , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Dove Medical Press
2018
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6311322/ https://ncbi.nlm.nih.gov/pubmed/30643398 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S173595 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|